NANOMICRO(SH:688690)2024-04-24 10:50Financial Performance - The net profit attributable to shareholders increased by 36.66% year-on-year, driven by the recovery in operating income[9] - The net profit excluding non-recurring gains and losses increased by 126.08% year-on-year[9] - The company reported a basic earnings per share of CNY 36.48, reflecting significant growth compared to the previous year[9] - Net profit attributable to shareholders for Q1 2024 was RMB 1,688.93 million, representing a 36.66% increase compared to the same period last year[30] - The net profit after deducting non-recurring gains and losses was RMB 1,353.42 million, showing a substantial increase of 126.08% year-over-year[30] - Basic earnings per share for Q1 2024 were RMB 0.0419, up by 36.48% from the previous year[30] - Total revenue for Q1 2024 reached ¥154,098,720.18, an increase of 16.6% compared to ¥132,113,888.95 in Q1 2023[60] - Net profit for Q1 2024 was ¥14,642,335.59, up 65.5% from ¥8,844,695.02 in Q1 2023[50] - Operating profit for Q1 2024 was ¥19,332,551.34, an increase from ¥13,610,162.34 in Q1 2023[60] - The total comprehensive income for Q1 2024 was ¥14,675,123.14, compared to ¥8,676,508.73 in Q1 2023[50] Assets and Liabilities - The company's total assets increased by 8.01% to CNY 229,694.86 million compared to the end of the previous year[4] - Total liabilities increased to ¥465,461,270.83 in the latest report, up from ¥396,404,010.92[47] - Total equity rose to ¥1,831,487,296.98, compared to ¥1,730,164,277.45 in the previous period[47] - The company's cash and cash equivalents as of March 31, 2024, were RMB 293,988,172.12, down from RMB 339,764,974.75 at the end of 2023[45] - Accounts receivable increased to RMB 256,212,329.62 from RMB 197,305,569.01 year-over-year, indicating growth in sales[45] - Inventory levels rose to RMB 329,541,239.75, compared to RMB 272,177,803.18 in the previous year, suggesting increased stock levels[45] - The company’s total assets reached ¥2,296,948,567.81, up from ¥2,126,568,288.37 in the previous period[47] Cash Flow - The net cash flow from operating activities for the period was CNY 9,177.9 million, with notable reductions in cash payments for procurement, salaries, and taxes[9] - The company's operating cash flow for Q1 2024 was RMB 9,177,879.67, a significant improvement compared to a negative cash flow of RMB -24,775,316.82 in Q1 2023[26] - The total cash inflow from operating activities was RMB 143,694,631.67, while cash outflow was RMB 134,516,752.00, resulting in a net cash inflow[26] - The net cash flow from investing activities was -¥14,680,684.84, a significant decrease compared to ¥88,263,136.42 from the previous period[63] - Cash inflow from financing activities totaled ¥14,089,759.11, down from ¥67,900,000.00 in the prior period[63] - The net cash flow from financing activities was -¥40,233,339.19, contrasting with a positive flow of ¥64,338,898.88 previously[63] - The ending balance of cash and cash equivalents was ¥293,987,971.63, down from ¥377,117,428.47 at the end of the previous period[63] Research and Development - Research and development expenses totaled CNY 4,177.58 million, accounting for 27.11% of operating income, a decrease of 1.72 percentage points[4] - Research and development expenses for Q1 2024 totaled ¥41,775,828.89, compared to ¥38,089,598.74 in Q1 2023, reflecting a growth of 7.1%[60] Strategic Initiatives - The company plans to accelerate new product development and enhance internal marketing efforts due to significant declines in the protein chromatography instrument business[9]